[go: up one dir, main page]

DK3097085T3 - Benzoxazinonderivater til behandling af hudsygdomme - Google Patents

Benzoxazinonderivater til behandling af hudsygdomme Download PDF

Info

Publication number
DK3097085T3
DK3097085T3 DK15740572.1T DK15740572T DK3097085T3 DK 3097085 T3 DK3097085 T3 DK 3097085T3 DK 15740572 T DK15740572 T DK 15740572T DK 3097085 T3 DK3097085 T3 DK 3097085T3
Authority
DK
Denmark
Prior art keywords
treatment
skin diseases
benzoxazine derivatives
benzoxazine
derivatives
Prior art date
Application number
DK15740572.1T
Other languages
English (en)
Inventor
Göran Leonardsson
Fredrik Wågberg
Original Assignee
Sixera Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma Ab filed Critical Sixera Pharma Ab
Application granted granted Critical
Publication of DK3097085T3 publication Critical patent/DK3097085T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/201,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK15740572.1T 2014-01-23 2015-01-22 Benzoxazinonderivater til behandling af hudsygdomme DK3097085T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (1)

Publication Number Publication Date
DK3097085T3 true DK3097085T3 (da) 2020-10-26

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15740572.1T DK3097085T3 (da) 2014-01-23 2015-01-22 Benzoxazinonderivater til behandling af hudsygdomme

Country Status (18)

Country Link
US (2) US9695194B2 (da)
EP (1) EP3097085B1 (da)
JP (1) JP6448651B2 (da)
CN (1) CN106132941B (da)
AU (1) AU2015209761B2 (da)
CA (1) CA2934025C (da)
CY (1) CY1123477T1 (da)
DK (1) DK3097085T3 (da)
ES (1) ES2820868T3 (da)
HR (1) HRP20201500T1 (da)
HU (1) HUE051296T2 (da)
LT (1) LT3097085T (da)
PL (1) PL3097085T3 (da)
PT (1) PT3097085T (da)
RS (1) RS60830B1 (da)
SI (1) SI3097085T1 (da)
SM (1) SMT202000557T1 (da)
WO (1) WO2015112081A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6448651B2 (ja) * 2014-01-23 2019-01-09 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体
CN107531622B (zh) * 2015-05-13 2020-03-20 日本农药株式会社 邻氨基苯甲酸酯化合物或其盐类和含有该化合物的农业园艺用杀菌剂及其使用方法
US10821094B2 (en) * 2016-01-13 2020-11-03 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
US11773154B2 (en) 2017-06-16 2023-10-03 Azitra Inc Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2020359526A1 (en) * 2019-10-01 2022-04-21 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as KLK5/7 dual inhibitors
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
CN117396188A (zh) 2021-06-01 2024-01-12 西可斯拉制药公司 6-乙氧基-7-甲氧基-2-(2-甲基硫基苯基)-3,1-苯并噁嗪-4-酮的水包油乳液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
AU2826099A (en) 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
CA2525383C (en) * 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物,其製備方法以及包含有此等衍生物的藥學組成物
JP6448651B2 (ja) * 2014-01-23 2019-01-09 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体

Also Published As

Publication number Publication date
JP6448651B2 (ja) 2019-01-09
US9695194B2 (en) 2017-07-04
PT3097085T (pt) 2020-10-08
CN106132941B (zh) 2018-04-06
EP3097085A1 (en) 2016-11-30
US20170267692A1 (en) 2017-09-21
LT3097085T (lt) 2020-10-12
US20170002021A1 (en) 2017-01-05
AU2015209761A1 (en) 2016-07-07
AU2015209761B2 (en) 2018-11-29
CA2934025A1 (en) 2015-07-30
CA2934025C (en) 2022-06-07
US10072024B2 (en) 2018-09-11
SI3097085T1 (sl) 2020-11-30
EP3097085A4 (en) 2017-08-09
WO2015112081A1 (en) 2015-07-30
ES2820868T3 (es) 2021-04-22
JP2017503798A (ja) 2017-02-02
HUE051296T2 (hu) 2021-03-01
CN106132941A (zh) 2016-11-16
HRP20201500T1 (hr) 2020-12-25
SMT202000557T1 (it) 2020-11-10
RS60830B1 (sr) 2020-10-30
CY1123477T1 (el) 2022-03-24
EP3097085B1 (en) 2020-07-29
PL3097085T3 (pl) 2021-01-11

Similar Documents

Publication Publication Date Title
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3728271T3 (da) Makrocykliske forbindelser til behandling af sygdomme
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3211071T3 (da) Fremstillingsfremgangsmåde til retinalt væv
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3210973T3 (da) Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
DK3185867T3 (da) Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
DK3855181T3 (da) Forbindelser til behandling af lipofuscinrelaterede sygdomme
DK3096775T5 (da) SOCS-mimetika til behandling af sygdomme
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
DK3200783T3 (da) Behandling af erytromelalgi